Related Experiment Videos
[Clinical observations during accumulative oral glycoside therapy with meproscillarin (author's transl)]
Abstract:
In heart failure of the severity degrees II and III according to Friedberg's classification, administration of a daily maintenance dose of 0.5--0.75 mg of 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (mesproscillarin, Clift) induces a cumulative blood level of 1--1.5 mg after 8--10 days. This level eliminates manifestations of heart failure both clinically and with regard to objective criteria. Increased heart rate returns to normal particularly in types of the tachycardiac atrial fibrillation. The frequency corrected QT-time is significantly reduced by about 30 ms. The relative heart volume decreases. The heart's work is increased by about 15%. No side effects are observed under this oral accumulative glycoside therapy.
Insights
This study shows that mesproscillarin effectively treats heart failure (HF) by normalizing heart rate and reducing heart volume. This oral glycoside therapy demonstrates significant clinical benefits with no observed side effects in patients with moderate to severe heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) of severity degrees II and III requires effective treatment.
- Current therapies may have limitations or side effects.
Purpose of the Study:
- To evaluate the efficacy and safety of mesproscillarin in treating moderate to severe heart failure.
- To assess the pharmacokinetic and pharmacodynamic effects of mesproscillarin therapy.
Main Methods:
- Administration of a daily maintenance dose of 0.5–0.75 mg of mesproscillarin (14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide).
- Monitoring of cumulative blood levels, clinical manifestations, and objective criteria of heart failure.
- Assessment of heart rate, QT-time, relative heart volume, and cardiac work.
Main Results:
- A cumulative blood level of 1–1.5 mg was achieved after 8–10 days.
- Elimination of clinical and objective signs of heart failure.
- Normalization of increased heart rate, particularly in tachycardiac atrial fibrillation.
- Significant reduction in frequency-corrected QT-time (approx. 30 ms).
- Decrease in relative heart volume and an approximate 15% increase in heart's work.
Conclusions:
- Mesproscillarin is an effective oral accumulative glycoside for treating heart failure (HF) of severity degrees II and III.
- The therapy leads to significant improvements in cardiac function and clinical status.
- No adverse side effects were observed during the oral mesproscillarin therapy.